STOCK TITAN

Tang Capital reports 0% stake in Keros Therapeutics (NASDAQ: KROS)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Keros Therapeutics, Inc. received an amended ownership report showing that Tang Capital and related entities no longer hold any of its common stock. The Schedule 13G/A (Amendment No. 1) reports that Tang Capital Management, Kevin Tang, and affiliated funds beneficially own 0 shares, representing 0% of the Keros common stock class as of the event date of 12/31/2025. The filing also confirms they have no sole or shared voting or dispositive power over any Keros shares and certifies the holdings are not intended to influence control of the company.

Positive

  • None.

Negative

  • None.

Insights

Tang Capital and affiliates report reducing their Keros stake to zero.

Tang Capital Management, Kevin Tang, and several affiliated entities now report beneficial ownership of 0 Keros Therapeutics common shares, or 0% of the class, as of 12/31/2025. All sole and shared voting and dispositive powers are listed as zero.

This Schedule 13G/A (Amendment No. 1) indicates that a previously reportable ownership position has fallen to 5% or less of the class and is now reported as 0%. The certification states the securities were not acquired or held for the purpose of changing or influencing control of Keros.

The practical impact depends on how important Tang Capital was as a historical shareholder, which is not detailed here. Future company filings may provide additional context on the evolving shareholder base and any new large holders that might emerge.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



TANG CAPITAL MANAGEMENT, LLC
Signature:/s/ Kevin Tang
Name/Title:Manager
Date:02/17/2026
KEVIN TANG
Signature:/s/ Kevin Tang
Name/Title:Self
Date:02/17/2026
TANG CAPITAL PARTNERS, LP
Signature:/s/ Kevin Tang
Name/Title:Manager, Tang Capital Management, LLC, General Partner
Date:02/17/2026
TANG CAPITAL PARTNERS INTERNATIONAL, LP
Signature:/s/ Kevin Tang
Name/Title:Manager, Tang Capital Management, LLC, General Partner
Date:02/17/2026
TANG CAPITAL PARTNERS III, INC
Signature:/s/ Kevin Tang
Name/Title:Chief Executive Officer
Date:02/17/2026
TANG CAPITAL PARTNERS IV, INC
Signature:/s/ Kevin Tang
Name/Title:Chief Executive Officer
Date:02/17/2026

FAQ

What does the KROS Schedule 13G/A filing report about Tang Capital's ownership?

The Schedule 13G/A shows Tang Capital Management, Kevin Tang, and affiliated entities now report beneficial ownership of 0 Keros shares, representing 0% of the common stock. All sole and shared voting and dispositive powers over Keros shares are also reported as zero.

Who are the reporting persons in the KROS Schedule 13G/A amendment?

The amendment lists Tang Capital Management, LLC, Kevin Tang, Tang Capital Partners, Tang Capital Partners International, Tang Capital Partners III, Inc., and Tang Capital Partners IV, Inc. as reporting persons, each disclosing beneficial ownership of 0 shares of Keros common stock.

What percentage of Keros (KROS) does Tang Capital now own according to this filing?

According to the Schedule 13G/A, Tang Capital Management, Kevin Tang, and all related entities now own 0% of Keros Therapeutics’ common stock. The filing’s ownership section states an aggregate beneficially owned amount of 0 shares, corresponding to 0% of the class.

What is the event date referenced in the Keros Therapeutics Schedule 13G/A?

The ownership change reported in the Schedule 13G/A is tied to an event date of 12/31/2025. As of that date, Tang Capital Management, Kevin Tang, and affiliated entities report beneficial ownership of 0 Keros common shares and 0% of the outstanding class.

Does Tang Capital indicate any intent to influence control of Keros Therapeutics in this filing?

The certification section states the securities referred to were not acquired and are not held for the purpose of changing or influencing control of Keros. It further notes they are not held in connection with any transaction having that purpose, except certain nomination-related activities referenced in the rule.

What type of security is covered in this KROS Schedule 13G/A amendment?

The filing covers common stock of Keros Therapeutics, Inc., with a par value of $0.0001 per share and CUSIP 492327101. The reporting persons collectively disclose beneficial ownership of 0 shares of this security class and no voting or dispositive power.
Keros Therapeutics, Inc.

NASDAQ:KROS

KROS Rankings

KROS Latest News

KROS Latest SEC Filings

KROS Stock Data

492.64M
28.54M
Biotechnology
Pharmaceutical Preparations
Link
United States
LEXINGTON